A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
Clinical trial NCT06832202 · RECRUITING
Trial details
- NCT number
- NCT06832202
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-16
- Primary completion
- 2027-06-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.